抗微生物剤の処方箋は良いものです. アミノグリコシドは,アミノグリコシドである.

Identifying markers of cachexia and nutritional deficit on radical radiotherapy outcomes in lung and head and neck cancer.

Current opinion in supportive and palliative care·2026

Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer.

ESMO open·2022

Screening two biodegradable polymers in enhanced efficiency fertiliser formulations reveals the need to prioritise performance goals.

Journal of environmental management·2021

RAPD typing of clinical isolates of Staphylococcus haemolyticus.

Letters in applied microbiology·2021

Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2019

The stability of imaging biomarkers in radiomics: a framework for evaluation.

Physics in medicine and biology·2019

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Coexisting Pyogenic and Tuberculous Liver Abscess in Uncontrolled Diabetes: A Diagnostic Challenge.

Clinical case reports·2026

Clinical characteristics, drug resistance profiles, and inflammatory cytokine signatures in newly treated versus retreated MDR/RR-TB patients: associations with treatment outcomes.

Frontiers in microbiology·2026

Blood Metabolites Mediate the Effects of Gut Microbiota on Diabetic Nephropathy: A Mendelian Randomization Study.

International journal of endocrinology·2026

Alarming levels of fluoroquinolone resistance among MDR-TB patients in Poland: molecular and phenotypic analysis.

Frontiers in cellular and infection microbiology·2026

Scalp microbiome in male androgenetic alopecia: <i>16S</i> rRNA sequencing-based clinical characterization, mouse model validation, and effects on hair follicle cells.

Frontiers in cellular and infection microbiology·2026

Biomarkers in QuantiFERON Supernatants May Help Distinguish Latent Tuberculosis Infection From Active Tuberculosis: Preliminary Report.

Mediators of inflammation·2026

関連する実験動画

抗微生物剤の処方箋は良いものです. アミノグリコシドは,アミノグリコシドである.

関連する概念動画

Identifying markers of cachexia and nutritional deficit on radical radiotherapy outcomes in lung and head and neck cancer.

Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer.

Screening two biodegradable polymers in enhanced efficiency fertiliser formulations reveals the need to prioritise performance goals.

RAPD typing of clinical isolates of Staphylococcus haemolyticus.

Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer.

The stability of imaging biomarkers in radiomics: a framework for evaluation.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Coexisting Pyogenic and Tuberculous Liver Abscess in Uncontrolled Diabetes: A Diagnostic Challenge.

Clinical characteristics, drug resistance profiles, and inflammatory cytokine signatures in newly treated versus retreated MDR/RR-TB patients: associations with treatment outcomes.

Blood Metabolites Mediate the Effects of Gut Microbiota on Diabetic Nephropathy: A Mendelian Randomization Study.

Alarming levels of fluoroquinolone resistance among MDR-TB patients in Poland: molecular and phenotypic analysis.

Scalp microbiome in male androgenetic alopecia: <i>16S</i> rRNA sequencing-based clinical characterization, mouse model validation, and effects on hair follicle cells.

Biomarkers in QuantiFERON Supernatants May Help Distinguish Latent Tuberculosis Infection From Active Tuberculosis: Preliminary Report.

関連する実験動画

抗微生物剤の処方箋は良いものです. アミノグリコシドは,アミノグリコシドである.

関連する概念動画

関連記事